key: cord-0919508-2lmmywan authors: da Silva, Gustavo Figueiredo; da Silva, Caroline Figueiredo; Oliveira, Raddib Eduardo Noleto da Nobrega; Romancini, Fabiana; Mendes, Rafael Marques; Locks, Amanda; Longo, Maria Francisca Moro; Moro, Carla Heloisa Cabral; Longo, Alexandre Luiz; Braatz, Vera Lucia title: Guillain–Barré syndrome after coronavirus disease 2019 vaccine: A temporal association date: 2021-10-26 journal: Clin Exp Neuroimmunol DOI: 10.1111/cen3.12678 sha: d77385b2e8e13f2f415c6a23a83908ac46e5f117 doc_id: 919508 cord_uid: 2lmmywan BACKGROUND: Guillain–Barré syndrome (GBS) is an acute monophasic immune‐mediated polyradiculoneuropathy, preceded by gastrointestinal or respiratory infections in up to two‐thirds of patients. On rare occasions, people develop GBS after vaccination, but no causal association has been proven. In the current coronavirus disease 2019 (COVID‐19) pandemic, some cases have been reported associating COVID‐19 vaccine with GBS. CASE PRESENTATION: We report a case of a 62‐year‐old woman with GBS after the first dose of the Oxford/AstraZeneca vaccine against SARS‐CoV‐2. The symptoms started 3 weeks after the vaccine, and were characterized by ascending and progressive paresthesia in the upper and lower limbs, followed by loss of strength of the upper limbs and dysphagia for solids. The hypothesis of GBS was confirmed by clinical presentation compatible with albuminocytologic dissociation in cerebrospinal fluid and based on the Brighton criteria level 2. The treatment was a 5‐day course of intravenous immunoglobulin with an improvement of symptoms. CONCLUSIONS: In the absence of other causes, the diagnosis of GBS was made, with evidence of a clear temporal association with COVID‐19 vaccine. However, a cautious position is important when assigning a particular side‐effect directly to a vaccine. It is important to emphasize that it is a temporal association only and the benefits of COVID‐19 vaccination continue to outweigh the possible consequences. classified as level 1 (high level of diagnostic certainty) to level 3 (lowest level of diagnostic certainty). 3 In addition, treatment mainly consists of the use of intravenous immunoglobulin or plasma exchange, alongside supportive care. 1 Molecular mimicry and immune-mediated phenomena are the most likely causes associated with the physiopathology of the disease. On rare occasions, GBS develops after vaccination, but no cause-effect relationship has been proven. In late 1976, the administration of outmoded anti-rabies vaccines and the swine influenza vaccine campaign in the USA were associated with an increase in the number of GBS cases. 2 In the SARS-CoV-2 pandemic, some cases have been reported with temporal association between coronavirus disease 2019 (COVID-19) vaccine and development of GBS. Hence, the present study aimed to describe a case of GBS with temporal association with the first dose of the Oxford/AstraZeneca COVID-19 vaccine. A 62-year-old white Brazilian woman, with clinical history of high blood pressure and congestive heart failure, received a first dose of Oxford/AstraZeneca COVID-19 vaccine. A total of 18 days later, the patient presented paresthesia of the distal extremities of the lower limbs with ascending progression. At her baseline, she was able to carry out her daily routine and walk without assistance, with a modified Rankin scale score of 1 and Hughes grade scale for assessing functional motor deficits score of 0, which is normal. 4 GBS is the most frequently diagnosed cause of acute polyneuropathy, although its etiology is not completely defined. 2 Vaccinations have been associated with GBS, mainly H1N1 immunization. However, the association between the influenza vaccine and GBS remains weak, and the presence of both is to be considered a rare event. An incidence rate of 1.6 cases of GBS per 1 000 000 was noted after the 2009 H1N1 influenza A vaccination. 6 Regarding the COVID-19 vaccine, we found reports of GBS variant after the Oxford/AstraZeneca vaccine and with the Pfizer vaccine (Table 1) Caution should be exercised when assigning any particular sideeffect directly to a vaccine. It is essential to highlight that the incidence of GBS associated with the Oxford/AstraZeneca COVID-19 vaccine remains rare and the vaccination benefits continue to outweigh possible risks. Monitoring for vaccine side-effects and carrying out broad-spectrum observational studies are necessary to establish a better understanding between the vaccines and GBS. • Approval of the research protocol: N/A. • Informed consent: All informed consent was obtained from the participant. • Registry and the Registration No. of the study/trial: N/A. • Animal studies: N/A. The authors declare no conflict of interest. Gustavo Figueiredo da Silva https://orcid. org/0000-0003-2508-1989 Guillain-Barré syndrome Case of Guillain-Barré syndrome following COVID-19 vaccine Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data Control trial of prednisolone in acute polyneuropathy Diagnosis and management of Guillain-Barré syndrome in ten steps COVID-19 vaccine and Guillain-Barré syndrome: let's not leap to associations Guillain-Barré syndrome variant occurring after SARS-CoV-2 vaccination Guillain-Barré syndrome following ChAdOx1-S / nCoV -19 vaccine Neurological complications of COVID-19: Guillain-Barre syndrome following Pfizer COVID-19 vaccine